Precursor B-cell acute lymphoblastic leukemia in remission

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%

The incidence of grade >=3 infection during the bridging period was significantly higher in patients who received >=2 cycles of bridging chemotherapy compared to 1 cycle (94% versus 56%, p=0.019).

Effect: adverse; 94% vs 56%